Floatz logo

Natalizumab

Primary Progressive Multiple Sclerosis

Rigshospitalet, DenmarkPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Primary Progressive Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Ocrevus
Indapta Therapeutics, INC.
Phase 4BBB
Fampridine
University College Dublin
Phase 4BBB
Fampridine
University College Dublin
Phase 4BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Rigshospitalet, Denmark
Phase 3B
DEXAMETHASONE
Hoffmann-La Roche
Phase 3B

View all 46 →

Same molecule, other indications

Natalizumab is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
79 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →
secondary progressive multiple sclerosisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →